The content on this site is intended for healthcare professionals only
Dr Sara Hurvitz talks to ecancer for the ESMO 2021 meeting about the interim results from the phase II coopERA BC study which looked at giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, oestrogen receptor-positive, HER2-negative, untreated early breast cancer.
She explains that the trial evaluates these treatments by comparing the change in proliferation of the tumour, as measured by marker Ki-67.
Dr Hurvitz reports that the relative Ki-67 reduction was greater, with more tumours exhibiting complete cell cycle arrest, in the giredestrant arm than in the anastrozole arm.
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer
Revolutionising myeloma treatment through immune profiling
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Latest in EGFR mutated NSCLC
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Overview of the management of HER2-low breast cancer patients
